Remarkable response of PD-1 antibody plus lenvatinib as the second-line treatment for combined hepatocellular-cholangiocarcinoma: Report of two cases.
暂无分享，去创建一个
[1] Kathryn J Fowler,et al. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] J. Furuse,et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma , 2018, Cancer science.
[3] T. Matysiak-Budnik,et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study , 2017, British Journal of Cancer.